{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T18:22:57Z","timestamp":1749406977614},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T00:00:00Z","timestamp":1524441600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union\u2019s Seventh Framework Programme for research","award":["FP7\/2007\u20132013"],"award-info":[{"award-number":["FP7\/2007\u20132013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12879-018-3077-x","type":"journal-article","created":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T12:32:12Z","timestamp":1524486732000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America"],"prefix":"10.1186","volume":"18","author":[{"given":"Yanink","family":"Caro-Vega","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Schultze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Marie","family":"W. Efsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank A.","family":"Post","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Panteleev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aliaksandr","family":"Skrahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose M.","family":"Miro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Girardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daria N.","family":"Podlekareva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens D.","family":"Lundgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Sierra-Madero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Toibaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Andrade-Villanueva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Tetradov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Fehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Cayl\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo H.","family":"Losso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert F.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Mocroft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole","family":"Kirk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda","family":"Crabtree-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,23]]},"reference":[{"key":"3077_CR1","volume-title":"Global tuberculosis report. World Health Organization","author":"WHO","year":"2014","unstructured":"WHO. Global tuberculosis report. World Health Organization, 2014."},{"issue":"18","key":"3077_CR2","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1097\/QAD.0b013e3283326879","volume":"23","author":"DN Podlekareva","year":"2009","unstructured":"Podlekareva DN, Mocroft A, Post FA, Riekstina V, Miro JM, Furrer H, et al. Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. AIDS. 2009;23(18):2485\u201395.","journal-title":"AIDS"},{"issue":"3","key":"3077_CR3","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1016\/S2352-3018(15)00252-0","volume":"3","author":"DN Podlekareva","year":"2016","unstructured":"Podlekareva DN, Efsen AM, Schultze A, Post FA, Skrahina AM, Panteleev A, et al. Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study. Lancet HIV. 2016;3(3):e120\u201331.","journal-title":"Lancet HIV"},{"issue":"2","key":"3077_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/00002030-200101260-00002","volume":"15","author":"YD Mukadi","year":"2001","unstructured":"Mukadi YD, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS. 2001;15(2):143\u201352.","journal-title":"AIDS"},{"key":"3077_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2334-9-46","volume":"9","author":"J Zhou","year":"2009","unstructured":"Zhou J, Elliott J, Li PC, Lim PL, Kiertiburanakul S, Kumarasamy N, et al. Risk and prognostic significance of tuberculosis in patients from the TREAT Asia HIV observational database. BMC Infect Dis. 2009;9:46.","journal-title":"BMC Infect Dis"},{"issue":"15","key":"3077_CR6","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1097\/QAD.0000000000000802","volume":"29","author":"RK Gupta","year":"2015","unstructured":"Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS. 2015;29(15):1987\u20132002.","journal-title":"AIDS"},{"key":"3077_CR7","doi-asserted-by":"publisher","first-page":"27048","DOI":"10.3402\/gha.v8.27048","volume":"8","author":"TT Balcha","year":"2015","unstructured":"Balcha TT, Skogmar S, Sturegard E, Bjorkman P, Winqvist N. Outcome of tuberculosis treatment in HIV-positive adults diagnosed through active versus passive case-finding. Glob Health Action. 2015;8:27048.","journal-title":"Glob Health Action"},{"key":"3077_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12981-016-0106-y","volume":"13","author":"W Manosuthi","year":"2016","unstructured":"Manosuthi W, Wiboonchutikul S, Sungkanuparph S. Integrated therapy for HIV and tuberculosis. AIDS Res Ther. 2016;13:22.","journal-title":"AIDS Res Ther"},{"issue":"16","key":"3077_CR9","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1056\/NEJMoa1013607","volume":"365","author":"DV Havlir","year":"2011","unstructured":"Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365(16):1482\u201391.","journal-title":"N Engl J Med"},{"issue":"16","key":"3077_CR10","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMoa1013911","volume":"365","author":"FX Blanc","year":"2011","unstructured":"Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365(16):1471\u201381.","journal-title":"N Engl J Med"},{"issue":"16","key":"3077_CR11","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1056\/NEJMoa1014181","volume":"365","author":"SS Abdool Karim","year":"2011","unstructured":"Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011;365(16):1492\u2013501.","journal-title":"N Engl J Med"},{"issue":"8","key":"3077_CR12","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1056\/NEJMoa0905848","volume":"362","author":"SS Abdool Karim","year":"2010","unstructured":"Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362(8):697\u2013706.","journal-title":"N Engl J Med"},{"issue":"3","key":"3077_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S0962-8479(05)80007-3","volume":"76","author":"S Schwander","year":"1995","unstructured":"Schwander S, Rusch-Gerdes S, Mateega A, Lutalo T, Tugume S, Kityo C, et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Tuber Lung Dis. 1995;76(3):210\u20138.","journal-title":"Tuber Lung Dis"},{"issue":"3","key":"3077_CR14","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/jac\/dkt446","volume":"69","author":"JY Chien","year":"2014","unstructured":"Chien JY, Chien ST, Huang SY, Yu CJ. Safety of rifabutin replacing rifampicin in the treatment of tuberculosis: a single-Centre retrospective cohort study. J Antimicrob Chemother. 2014;69(3):790\u20136.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"3077_CR15","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1097\/QAI.0000000000000515","volume":"68","author":"TM Rawson","year":"2015","unstructured":"Rawson TM, Brima N, Almajid F, Pozniak AL, Janmohamed A, Mandalia S, et al. Outcomes from treating tuberculosis with rifampicin or rifabutin in HIV-infected persons also receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2015;68(5):e84\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3077_CR16","unstructured":"WHO. Priority research questions for tuberculosis\/human immunodeficiency virus (TB\/HIV) in HIV-prevalent and resource-limited settings. Geneva: World Health Organization; 2010."},{"key":"3077_CR17","volume-title":"Tuberculosis care with TB-HIV co-management : integrated Management of Adolescent and Adult Illness (IMAI)","author":"WHO","year":"2007","unstructured":"WHO. Tuberculosis care with TB-HIV co-management : integrated Management of Adolescent and Adult Illness (IMAI). 2007."},{"key":"3077_CR18","volume-title":"Guidelines for national programmes and other stakeholders","author":"WHO","year":"2012","unstructured":"WHO. Guidelines for national programmes and other stakeholders. 2012."},{"key":"3077_CR19","doi-asserted-by":"crossref","unstructured":"Migliori GB, Zellweger JP, Abubakar I, Ibraim E, Caminero JA, De Vries G, et al. European union standards for tuberculosis care. Eur Respir J. 2012;39(4):807\u201319.","DOI":"10.1183\/09031936.00203811"},{"key":"3077_CR20","unstructured":"National Association Phthisiology. Clinical recommendations diagnosis and treatment of tuberculosis respiratory organs in adults, (homepage on the Internet). 2008 (cited 2017 Jan 17). Available from: Russia, Web site: http:\/\/itpcru.org\/wpcontent\/uploads\/2014\/09\/Klinicheskie-rekomendatsii-TB-RF-2014.pdf ."},{"key":"3077_CR21","unstructured":"Departamentul Central De Management Al Pnct. GUIDE implementation methodology of the National Tuberculosis Control, (homepage on the Internet). 2007 (cited 2017 Jan 17). Available from: Rumania, Web site: http:\/\/www.srp.ro\/ghiduri\/Ghid%20metodologic%20TBC%202007-2011.doc ."},{"key":"3077_CR22","unstructured":"Agenda of the Minister of Health. Appendix to the Bulletin of the National Center for. AIDS. (homepage on the Internet). 2011 (cited 2017 Jan 17). Available from: Poland, Web site: http:\/\/www.aids.gov.pl\/pobierz\/1642\/ ."},{"issue":"1","key":"3077_CR23","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1097\/QAI.0b013e3182a39979","volume":"65","author":"D Avila","year":"2014","unstructured":"Avila D, Althoff KN, Mugglin C, Wools-Kaloustian K, Koller M, Dabis F, et al. Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr. 2014;65(1):e8\u201316.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"3077_CR24","doi-asserted-by":"publisher","first-page":"e20272","DOI":"10.1371\/journal.pone.0020272","volume":"6","author":"B Crabtree-Ramirez","year":"2011","unstructured":"Crabtree-Ramirez B, Caro-Vega Y, Shepherd BE, Wehbe F, Cesar C, Cortes C, et al. Cross-sectional analysis of late HAART initiation in Latin America and the Caribbean: late testers and late presenters. PLoS One. 2011;6(5):e20272.","journal-title":"PLoS One"},{"key":"3077_CR25","doi-asserted-by":"publisher","unstructured":"Mocroft A, Lundgren J, Antinori A, Monforte A, Brannstrom J, Bonnet F, et al. Late presentation for HIV care across Europe: update from the collaboration of observational HIV epidemiological research Europe (COHERE) study, 2010 to 2013. Euro Surveill. 2015;20(47) https:\/\/doi.org\/10.2807\/1560-7917.ES.2015.20.47.30070 .","DOI":"10.2807\/1560-7917.ES.2015.20.47.30070"},{"issue":"5","key":"3077_CR26","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1001\/jama.300.5.530","volume":"300","author":"A Boulle","year":"2008","unstructured":"Boulle A, Van Cutsem G, Cohen K, Hilderbrand K, Mathee S, Abrahams M, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA. 2008;300(5):530\u20139.","journal-title":"JAMA"},{"issue":"9","key":"3077_CR27","doi-asserted-by":"publisher","first-page":"e44793","DOI":"10.1371\/journal.pone.0044793","volume":"7","author":"RA Murphy","year":"2012","unstructured":"Murphy RA, Marconi VC, Gandhi RT, Kuritzkes DR, Sunpath H. Coadministration of lopinavir\/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa. PLoS One. 2012;7(9):e44793.","journal-title":"PLoS One"},{"issue":"8","key":"3077_CR28","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.3851\/IMP1455","volume":"14","author":"G Maartens","year":"2009","unstructured":"Maartens G, Decloedt E, Cohen K. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. Antivir Ther. 2009;14(8):1039\u201343.","journal-title":"Antivir Ther"},{"issue":"11","key":"3077_CR29","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.5588\/ijtld.14.0143","volume":"18","author":"PA Minchella","year":"2014","unstructured":"Minchella PA, Armitage AE, Darboe B, Jallow MW, Drakesmith H, Jaye A, et al. Elevated hepcidin at HIV diagnosis is associated with incident tuberculosis in a retrospective cohort study. Int J Tuberc Lung Dis. 2014;18(11):1337\u20139.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"3077_CR30","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1473-3099(14)70711-X","volume":"14","author":"B Grinsztejn","year":"2014","unstructured":"Grinsztejn B, De Castro N, Arnold V, Veloso VG, Morgado M, Pilotto JH, et al. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. Lancet Infect Dis. 2014;14(6):459\u201367.","journal-title":"Lancet Infect Dis"},{"key":"3077_CR31","unstructured":"CDC. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis Available from: www.cdc.gov\/tb\/publications\/guidelines\/tb_hiv_drugs\/recommendations03.htm ."},{"issue":"6","key":"3077_CR32","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1097\/EDE.0b013e31823029dd","volume":"22","author":"CJ Howe","year":"2011","unstructured":"Howe CJ, Cole SR, Westreich DJ, Greenland S, Napravnik S, Eron JJ Jr. Splines for trend analysis and continuous confounder control. Epidemiology. 2011;22(6):874\u20135.","journal-title":"Epidemiology"},{"issue":"2","key":"3077_CR33","doi-asserted-by":"publisher","first-page":"Article 18","DOI":"10.2202\/1557-4679.1212","volume":"6","author":"LE Cain","year":"2010","unstructured":"Cain LE, Robins JM, Lanoy E, Logan R, Costagliola D, Hernan MA. When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data. Int J Biostat. 2010;6(2):Article 18.","journal-title":"Int J Biostat"},{"key":"3077_CR34","doi-asserted-by":"crossref","unstructured":"TB: HIV Study writing Group. One-year mortality of HIV-positive patients treated for rifampicin- and isoniazidsusceptible tuberculosis in Eastern Europe, Western Europe, and Latin America. AIDS. 2017;31(3):375\u201384.","DOI":"10.1097\/QAD.0000000000001333"},{"issue":"12","key":"3077_CR35","doi-asserted-by":"publisher","first-page":"e0145380","DOI":"10.1371\/journal.pone.0145380","volume":"10","author":"AM Efsen","year":"2015","unstructured":"Efsen AM, Schultze A, Post FA, Panteleev A, Furrer H, Miller RF, et al. Major challenges in clinical management of TB\/HIV Coinfected patients in Eastern Europe compared with Western Europe and Latin America. PLoS One. 2015;10(12):e0145380.","journal-title":"PLoS One"},{"issue":"1","key":"3077_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/QAI.0b013e31823d3aba","volume":"59","author":"IV Bassett","year":"2012","unstructured":"Bassett IV, Chetty S, Wang B, Mazibuko M, Giddy J, Lu Z, et al. Loss to follow-up and mortality among HIV-infected people co-infected with TB at ART initiation in Durban, South Africa. J Acquir Immune Defic Syndr. 2012;59(1):25\u201330.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"3077_CR37","doi-asserted-by":"publisher","first-page":"e0153921","DOI":"10.1371\/journal.pone.0153921","volume":"11","author":"B Crabtree-Ramirez","year":"2016","unstructured":"Crabtree-Ramirez B, Caro-Vega Y, Shepherd BE, Grinsztejn B, Wolff M, Cortes CP, et al. Time to HAART initiation after diagnosis and treatment of opportunistic infections in patients with AIDS in Latin America. PLoS One. 2016;11(6):e0153921.","journal-title":"PLoS One"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3077-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-018-3077-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3077-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T18:21:33Z","timestamp":1661019693000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-018-3077-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,23]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3077"],"URL":"https:\/\/doi.org\/10.1186\/s12879-018-3077-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,23]]},"assertion":[{"value":"28 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The HIV\/TB project was an observational study and patients were not exposed to any experimental interventions nor did the study intervene with the clinical management of the patient. The study only collected information from patient records and if necessary, patient interview. The study was conducted according to the current ethical standards including the WMA Declaration of Helsinki and was submitted to the appropriate regulatory authorities including ethical committees in the participating countries, as requested by local regulations. When informed consent was required by the local and\/or national Ethics Committees, this was obtained prior to the initiation of any study related data being obtained. The consent form was approved by the IEC\/IRB of each participating centre.In specific, IEC\/IRB were obtained from the following commitees:Le Comit\u00e9 d\u2019Ethique du C.H.U Saint-Pierre, Le Num\u00e9ra registre AK\/12\u201303-28\/4128, Comit\u00e9.\u00c9tico Cientifico del servicio de Salud Metropolitano Centra, Chil, certificado 452\/11, De.Videnskabsetiske Komiteer i Region Hovedstaden Journal nr.: H-3-2011-095, United Kingdom national ethics approval Reference nr. 11\/LO\/0713 & R&D Reference nr. CSP 75430 for UK sites: Mortimor Market Centre, London, Imperial College Healthcare, London, St. Marys Hospital, London, North Manchester General Hospital, Manchester, Sheffield Teaching Hospitals, Sheffield, King\u2019s College Hospital, London, North Middlesex University Hospital, London, Queen Elisabeth Hospital, London R&D ref. nr. SLHT\/2011\/UCSM\/HIV\/88, Leicester Royal Infirmary, Leicester. El Comit\u00e9 de Etica en Investigaci\u00f3n en Salud, Hospital Paroissien Argentina 20\/12\/2911, Comit\u00e9 de Etica Iniciativa y Reflextion Bioetica Hospital Pineiro & Hospital Ramos Mejia Argentina 12\/12\/12, Comit\u00e9 de Bio\u00e9tica Reg. nr. 11,743\/11 Hospital Nacional Profesor Alejandro Posdas Argentina, Comit\u00e9 Institucional de \u00c8tica de la Investigacion en Salud del Nino u del Adulto Cordoba 16\/12\/2012 Hospital Rawson, Comit\u00e9 de Etica La Plata 12\/11\/12 Hospital Sa Juan de Dios Argentina, Comit\u00e9 de \u00c9tica en Investigacion Buenos Aires 18\/11\/12 Hospital Santojani Argentina & 11\/05\/2012 Hospital Fracisco Javier Muniz Argentina, Docencia e Investigaci\u00f3n 15\/06\/12 Jujuy Argentina, Institutional Review Board Tbilisi Ref. nr. 12\u2013007, Registro delle Sperimentazioni del Comitato Etico Rone nr. 24\/2011 Spallanzani, Comitato Etico San Gerardo, Monza 26\/05\/2011, Comitato Etico Aziendale A.O.U. San Martino Genoa nr. 295 08\/04\/2011, Comitato Etico Indipendente Locale Policlinio Consorziale Bari nr. 624 28\/09\/2011, Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n Ref. nr 437, Comit\u00e9 de \u00c9tica del Hospital General Regional de Le\u00f3n 10\/10\/2011, Secretario del Comit\u00e9 de Ensenanza, Investigacion y \u00c9tica Hospital Civil de Guadalajara Invest. Nr. 038\/12, Comitato Etico Spedali Civili Brescia 07\/06\/2011 nr.36; Direcci\u00f3 General de Regularcio Barcelona CY-ANT-2011-01, Hospital Universitario Ram\u00f3n y Cajal Comit\u00e9 \u00c9tico de Investigaci\u00f3n Clinica 12\/07\/2011, Comite Etico de Investigation Clinica de Euscadi Vitoria 02\/02\/2012, Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica Hospital General Universitario Gregorio Maranon Madrid SAS\/3470\/2009, Kantonale Ethik-Kommission Z\u00fcrich EK-793, Ethical Committee of Rep. Res. And Practical Centre for Pulmonology Minsk 11\/02\/2011, Ethical Committee of Gomel State Medical University & Gomel Regional Centre for Hygiene, Ethical Committee for Botkin Hospital & City TB Hospital ref. nr.23, Ethical Committee for Novgorod Centre for AIDS Prevention and Control 11\/10\/2011, Ethican Committee of Samara State Medical University 10\/10\/2012, Komisja Bioetycznego Uniwersytetu Medycznego w Bialymstoku Poland R-I-00\/85c\/2012 \u2013R-I-002\/85\/2011, Tallinn Medical Research Ethics Committee Appr. Nr. 2555, RSU Etikas Komitejas Lemums Riga Nr. E-9(2), Vilniaus Regioninis Biomedicininiu Tyrimu Etikos Komitetas Nr. 158,200\u201307\u2013363-90, Dr. Victor Babes Hospital Institutional Ethics Committee nr. 3889, Ethics Committee Crimean Republican AIDS Centre Nr. 462\u201313\u201308-12.The data storage and handling was protected in accordance with and approved by the Danish Data Protection Agency (Datatilsynet) under the Act on Processing of Personal Data (Act No. 429 of 31 May 2000) and European Commission Directive 95\/46\/EC.ExternalRef removed","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"YCV, AS1, AMWE, AP, AS2, DNP, JDL, ST, ML, JT, JF, JC, JAV have no competing interests to declare.FAP, received honoraria and\/or research funding from Abbvie, Gilead, ViiV, BMS, MSD and Janssen.JMM received a personal intensification research grant (number INT15\/00168) during 2016 from the Instituto de Salud Carlos III, Ministerio de Econom\u00eda y Competitividad, Madrid, Spain, and a personal 80:20 research grant from the Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, during 2017\u201319.RFM has received honoraria from Gilead, Janssen, Merck, and ViiV for giving non-promotional lectures on clinical aspects of HIV; is a member of the British HIV Association Tuberculosis\/HIV Guidelines Committee; and is a panel member for the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents (National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association of the Infectious Diseases Society of America).JSM has received lecture fees, sponsorship, honoraria from Gilead, Stendhal, Abbvie, ViiV, Janssen and MSD.EG, Consultancy for Otsuka Novel Products, Speaker\u2019s fee from Janssen, Gilead sciences, Angelini, Research Grant from Gilead sciences, Travel Grant from Janssen.AM, has have received lecture fees, sponsorship, honoraria or consultancy fees from ViiV, Pfizer, BMS, BI, Merck and Wragge LLC.OK had prior board membership at ViiV Healthcare, Gilead Sciences and Merck, received payment for lectures and\/or for development of educational presentations from Abbott, Gilead Sciences, Tibotec and Quagen, and had travel\/accommodations\/meeting expenses paid by Abbott, BMS, Gilead Sciences, Merck and ViiV Healthcare \u2013 all outside the submitted work.BCR, has received lecture fees, sponsorship, honoraria from Gilead, Stendhal, Abbvie, Janssen and MSD.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"191"}}